A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer

(2019) Ivy X. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

(2019) Maxwell M. Sakyiamah et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Development of CXCR4 modulators based on the lead compound RB-108

(2019) Renren Bai et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis

(2019) Rui Wu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Head-to-tail macrocyclization of cysteine-free peptides using an o -aminoanilide linker

(2018) Takumi Ohara et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists

(2018) Zhanhui Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments

(2018) Mario Petrillo et al.   Future Oncology

Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties

(2018) Eric J. Miller et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)–Ligand Interactions on Living Cancer Cells

(2018) Diego Brancaccio et al.   JOURNAL OF MEDICINAL CHEMISTRY

Development of Stem-Cell-Mobilizing Agents Targeting CXCR4 Receptor for Peripheral Blood Stem Cell Transplantation and Beyond

(2018) Chien-Huang Wu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Defining the role of the tumor vasculature in antitumor immunity and immunotherapy

(2018) Marco B. Schaaf et al.   Cell Death & Disease

Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME Properties

(2018) Huy H. Nguyen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure–Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist

(2017) Salvatore Di Maro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology

(2017) Lun Kelvin Tsou et al.   MEDICINAL RESEARCH REVIEWS

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

(2017) Dylan J. Martini et al.   Journal for ImmunoTherapy of Cancer

CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer

(2015) Dong-Yu Gao et al.   BIOMATERIALS

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

(2015) Yunching Chen et al.   HEPATOLOGY

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

(2015) F Guo et al.   ONCOGENE

Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine

(2015) L. Qin et al.   SCIENCE

Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070

(2013) G O'Boyle et al.   BRITISH JOURNAL OF CANCER

Structure-based studies of chemokine receptors

(2013) Lan Zhu et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice

(2013) Yunching Chen et al.   HEPATOLOGY

Small Molecule Inhibitors of CXCR4

(2013) Bikash Debnath et al.   Theranostics

New Insight into the SDF-1/CXCR4 Axis in a Breast Carcinoma Model: Hypoxia-Induced Endothelial SDF-1 and Tumor Cell CXCR4 Are Required for Tumor Cell Intravasation

(2012) F. Jin et al.   MOLECULAR CANCER RESEARCH

Discovery of Novel Stem Cell Mobilizers That Target the CXCR4 Receptor

(2011) Chien-Huang Wu et al.   ChemMedChem

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression

(2010) Xueqing Sun et al.   CANCER AND METASTASIS REVIEWS

Roles of Chemokine Receptor 4 (CXCR4) and Chemokine Ligand 12 (CXCL12) in Metastasis of Hepatocellular Carcinoma Cells

(2010) Hui Liu et al.   Cellular & Molecular Immunology

Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists

(2010) B. Wu et al.   SCIENCE

Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma

(2009) Hye-Yoon Choi et al.   ANNALS OF PHARMACOTHERAPY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY